Rhone-poulenc Rorer Pharmaceuticals Inc.

Aventis Pharmaceuticals Inc.

Aventis Pharmaceuticals Products Inc.

Rorer Pharmaceutical Corporation

Histogen, Inc.

Aventis Pharma Deutschland, Gmbh

Rhone-poulenc Rorer International (holdings), Inc.

Aventis Pharmaceuticals Product, Inc.

Alfred P Spada

Michael R Myers

Martin P Maguire

Paul E Persons

Wei He

Henry F Campbell

William R Ewing

William L Studt

Donald E Kuhla

Yong Mi Choi-Sledeski

Cynthia Anne Fink

Henry W Pauls

Michael R Becker

Heinz W Pauls

Alexander Levitzki

Chaim Gilon

Scott I Klein

Kevin Richard Guertin

Roderick S Davis

Thomas Tucker

Aviv Gazit

Bruce F Molino

William C Faith

Daniel G McGarry

Daniel L Cheney

Asher Zilberstein

Susan E Johnson

Chin-Yi Jenny Hsu

Christopher J Burns

Timothy Francis Gallagher

Stephen M Condon

Robert J Ternansky

Kent W Neuenschwander

Joseph M Karpinski

Robert D Groneberg

Robert L Morris

Aiwen Li

Daniel Gerard McGarry

Gregory Bernard Poli

Barbara Hanney

Jean-Francois Sabuco

Benoit J Vanasse

John Ziqi Jiang

Mark A Bobko

Yong Gong

Laurence W Reilly

Yong-Mi Choi

Jonathan S Mason

Robert J Temansky

Michael Mueller

Wan F Lau

Cuong Q Ly

Martin P Maquire

Robert W Studt

Don D Cha

Jonathan Stephen Mason

Provided herein are compounds of formula I, compositions comprising the compounds and method of treating various diseases with the compounds and compositions.

Caspase inhibitors and methods of use thereof

The present invention relates to (S)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating e.g. cardiovascular, kidney, liver, lung, skin, joints, CNS, inflammatory and autoimmune diseases.

(S)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases

This invention is directed to oxoazaheterocycyl compounds which inhibit Factor Xa, to oxoazaheterocycyl compounds which inhibit both Factor Xa and Factor IIa, to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds, to a method of directly inhibiting Factor Xa and to a method of simultaneously directly inhibiting Factor Xa and Factor IIa.

Substituted oxoazaheterocyclyl compounds

This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor tyrosine kinase and/or Lck tyrosine kinase, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.

Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases

This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.

This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56 tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.

Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and /or p56lck tyrosine kinases

This invention relates to the modulation and/or inhibition of cell signaling, cell proliferation, cell inflammatory response, the control of abnormal cell growth and cell reproduction. More specifically, this invention relates to the use of mono- and/or bicyclic aryl or heteroaryl quinazoline compounds in inhibiting cell proliferation, including compounds which are useful protein tyrosine kinase (PTK) inhibitors. The method of treating cell proliferation and/or differentiation or mediator release using said quinazoline compounds and their use in pharmaceutical compositions is described.

Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase

Compounds having antihypertensive, cardioprotective anti-ischemic and antilipolytic properties

Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties

This invention relates to compounds of formula

Substituted N-&lsqb;(aminoiminomethyl or aminomethyl)phenyl&rsqb;propyl amides

Growing community of inventors

Lansdale, PA, United States of America

Alfred P Spada